Clinicopathological factors | Number of samples |
---|---|
Median age at diagnosis | 65 (range 32-85) |
Histological grade | |
Grade 1 | 18 (24%) |
Grade 2 | 38 (50.7%) |
Grade 3 | 19 (25.3%) |
Response | |
Progressive Disease | 7 (9.5%) |
PR, MC or SD | 67 (90.5%) |
Tumor size | |
T2 | 3 (4%) |
T3 | 47 (62.7%) |
T4 | 25 (33.3%) |
Lymph node metastasis | |
N0 | 25 (33.3%) |
N1 | 29 (38.7%) |
N2 | 21 (28%) |
Distant metastasis | |
M0 | 66 (88.0%) |
M1 | 9 (12%) |
Stage | |
Stage 2 | 18 (24%) |
Stage 3 | 46 (61%) |
Stage 4 | 11 (15%) |
TP53 mutations | |
Wild type | 55 (73.3%) |
Mutant | 20 (26.7%) |
Estrogen receptor status | |
Positive | 65 (86.7%) |
Negative | 10 (13.3%) |
Progesteron receptor status | |
Positive | 58 (77.3%) |
Negative | 17 (22.7%) |
ErbB2 receptor status | |
Positive | 11 (25%) |
Negative | 33 (75%) |
Survival | |
> 5 years | 20 (26.7%) |
< 5 years | 55 (73.3%) |